Insider Selling: Nkarta, Inc. (NASDAQ:NKTX) CEO Sells 6,126 Shares of Stock

Nkarta, Inc. (NASDAQ:NKTXGet Rating) CEO Paul J. Hastings sold 6,126 shares of the firm’s stock in a transaction dated Wednesday, September 21st. The shares were sold at an average price of $13.01, for a total value of $79,699.26. Following the sale, the chief executive officer now owns 274,335 shares in the company, valued at $3,569,098.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Nkarta Stock Performance

NKTX stock opened at $12.52 on Friday. The firm has a market cap of $609.22 million, a PE ratio of -4.52 and a beta of 0.07. The firm’s 50 day moving average price is $14.58 and its 200-day moving average price is $13.36. Nkarta, Inc. has a one year low of $7.55 and a one year high of $31.45.

Nkarta (NASDAQ:NKTXGet Rating) last released its quarterly earnings results on Thursday, August 11th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.11. Equities research analysts predict that Nkarta, Inc. will post -2.57 EPS for the current fiscal year.

Institutional Trading of Nkarta

Several institutional investors have recently added to or reduced their stakes in NKTX. Price T Rowe Associates Inc. MD increased its holdings in Nkarta by 64.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 3,879,662 shares of the company’s stock valued at $47,797,000 after purchasing an additional 1,520,473 shares during the last quarter. SR One Capital Management LP acquired a new stake in Nkarta in the 2nd quarter valued at approximately $16,427,000. Deep Track Capital LP acquired a new stake in Nkarta in the 4th quarter valued at approximately $19,409,000. State Street Corp increased its holdings in Nkarta by 392.0% in the 2nd quarter. State Street Corp now owns 1,359,615 shares of the company’s stock valued at $16,750,000 after purchasing an additional 1,083,297 shares during the last quarter. Finally, FMR LLC increased its holdings in Nkarta by 523,829.2% in the 2nd quarter. FMR LLC now owns 880,201 shares of the company’s stock valued at $10,844,000 after purchasing an additional 880,033 shares during the last quarter.

Analysts Set New Price Targets

NKTX has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Nkarta in a report on Wednesday. SVB Leerink assumed coverage on shares of Nkarta in a research note on Monday, July 18th. They issued an “outperform” rating and a $30.00 target price on the stock. Finally, Needham & Company LLC assumed coverage on shares of Nkarta in a research note on Thursday, July 28th. They issued a “buy” rating and a $26.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Nkarta currently has an average rating of “Buy” and an average target price of $39.63.

Nkarta Company Profile

(Get Rating)

Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

See Also

Insider Buying and Selling by Quarter for Nkarta (NASDAQ:NKTX)

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.